Evommune, Inc. (EVMN)

Evommune Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2024	Dec 31, 2023
Cash & Equivalents	61.84	16.26	29.02
Short-Term Investments	24.96	55.79	50.06
Cash & Cash Equivalents	86.8	72.04	79.08
Cash Growth	-	-8.91%	-
Other Current Assets	8.1	1.95	0.95
Total Current Assets	94.9	73.99	80.03
Property, Plant & Equipment	-	1.33	0.73
Goodwill and Intangibles	-	0.47	1.23
Other Long-Term Assets	-	0.27	0.25
Total Long-Term Assets	-	2.07	2.22
Total Assets	-	76.06	82.25
Accounts Payable	-	8.26	1.76
Deferred Revenue	-	3	-
Current Debt	-	0.49	0.77
Other Current Liabilities	10.09	16.23	4.33
Total Current Liabilities	10.09	27.98	6.86
Long-Term Debt	-	-	0.49
Other Long-Term Liabilities	-	0.54	3.25
Total Long-Term Liabilities	-	0.54	3.73
Total Liabilities	-	28.52	10.59
Total Debt	0.07	0.49	1.26
Debt Growth	-	-61.23%	-
Retained Earnings	-	-152.22	-83.91
Shareholders' Equity	-171.23	-144.24	-77.71
Net Cash (Debt)	86.72	71.55	77.83
Net Cash (Debt) Growth	-	-8.06%	-
Working Capital	84.8	46.01	73.18

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).